{
    "symbol": "CTIC",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 20:11:02",
    "content": " Today, we are delighted to report $12.3 million in net product revenue for the second quarter, driven by significant growth in VONJO awareness among health care providers in both the community and academic settings and an overall share of voice that exceeds that of our competitors. This impressive start to our launch is a direct reflection of our commercial team's execution, as well as the demand that exists among MF patients and their health care providers that is HCPs, who are in need of a safe, simple and effective treatment option that is VONJO. One, build VONJO awareness among myelofibrosis HCPs; two, drive adoption and utilization in our top accounts and high-potential prescribers; and three, ensure optimal patient access via securing effective payer coverage, as well as our patient support services called CTI Access. Net loss for the three months ended June 30th, 2022 was $22.7 million or $0.21 for basic and diluted loss per share compared to a net loss of $19.7 million or $0.21 per basic and diluted loss per share for the same period in 2021. Net loss for the six months ended June 30th, 2022 was $59.8 million or $0.57 for basic and diluted loss per share compared to a net loss of $36.9 million or $0.44 for basic and diluted loss per share for the same period in 2021."
}